Kailera Therapeutics
Kailera Therapeutics raises $400M Series A at $1.5B valuation
Quick Facts
Kailera Therapeutics: Series A Funding Round
Kailera Therapeutics has successfully raised $400M in Series A funding, reaching a valuation of $1.5B.
Company Overview
Developing obesity therapeutics with acquired pipeline
Funding Details
The Series A round was led by Atlas Venture, with participation from Bain Capital Life Sciences.
Company Information
- Headquarters: Cambridge, MA
- Founded: 2024
- Employees: 80+
- Category: Biotech
Investment
Kailera Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Atlas Venture: Verified investor in Series A
- Bain Capital Life Sciences: Verified investor in Series A
Key Investors
About the Author
Related Company Reports
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
HorizonStudio Raises $100M Growth to Transform Biotech
HorizonStudio has secured $100M Growth in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
StreamData Raises $15M Seed to Transform Biotech
StreamData has secured $15M Seed in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
